Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Scottish Medicines Consortium (SMC) have approved Sanofi's Toujeo, a new once-daily basal insulin for the treatment of adults with diabetes.
Subscribe to our email newsletter
Insulin glargine 300 units/mL is a concentrated formulation of the glargine molecule identified in Lantus (insulin glargine 100 units/mL).
It forms a compact subcutaneous depot with a reduced surface area. Switching from insulin glargine 300 units/mL to insulin glargine 100 units/mL increases risk of hypoglycaemic events, particularly in the first week.
Patients are urged to lower their dose by 20% in order to reduce this risk. Toujeo controls blood sugar in adults with diabetes mellitus and reduces A1C levels.
More than 250,000 people in Scotland are currently diagnosed with diabetes and it is projected to increase to an estimated 350,000 people by 2030.
Sanofi UK medical director David Williams said: "The approval of insulin glargine 300 units/mL in Scotland is a significant milestone for Sanofi as we expand our portfolio of medicines for patients with both type 1 and type 2 diabetes and reinforces our commitment to continue improving
the quality of diabetes care."
The European Medicines Agency and the US Food and Drug Administration have already licensed insulin glargine 300 units/mL. It is under review by other regulatory authorities globally.